2026-04-02——
TriNetX gives Regeneron licensed access to de-identified EHR data on about 300 million patients
A short entry: a summary of the public record, checked against its sources, not yet read and analysed by Gianluca. How the register works
On April 2, 2026, TriNetX and Regeneron Pharmaceuticals announced a strategic collaboration giving Regeneron licensed access to TriNetX's de-identified health data from approximately 300 million individuals to support drug discovery, development and digital health initiatives. Regeneron will invest up to $200 million in TriNetX as part of the collaboration.
What happened
- Announced April 2, 2026 by TriNetX and Regeneron Pharmaceuticals (NASDAQ: REGN).
- TriNetX will provide Regeneron with secure, licensed access to de-identified health data from approximately 300 million individuals, 170 million of whom are in the United States.
- Regeneron gains the exclusive opportunity to connect large-scale genomic and proteomic data cohorts to TriNetX's phenotypic data network.
- Data is sourced from TriNetX's global network of health system partners, described as over 11,000 healthcare provider locations.
- Matching of TriNetX data to Regeneron Genetics Center genomic and proteomic data will use privacy-preserving methods and comply with HIPAA and GDPR.
- Regeneron will invest up to $200 million in TriNetX as part of the collaboration.
Sources
- markets.ft.com — primary
- prnewswire.com — corroborating
Announced 2026-04-02